相关临床试验
5
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
2
40.0%
已完成
2
40.0%
招募中
1
20.0%
暂无批准数据
- 4Moving Biotech received FDA IND clearance for 4P004, enabling expansion of the Phase 2a INFLAM MOTION trial into the United States alongside existing sites in Europe and Canada. - The company is advancing the first clinical proof of concept for a first-in-class intra-articular GLP-1 receptor agonist targeting disease modification in osteoarthritis. - The INFLAM MOTION trial will enroll 129 patients with knee osteoarthritis and synovitis, with pain assessment at Week 4 as the primary endpoint and structural MRI evaluation at Week 12. - Preclinical studies demonstrated 4P004's ability to modulate multiple biological markers across the whole joint, supporting its potential as a disease-modifying osteoarthritis drug capable of slowing structural impairment.
- 4Moving Biotech has enrolled the first patient in INFLAM MOTION, a Phase 2a trial evaluating 4P004, an intra-articular GLP-1 analog for knee osteoarthritis treatment. - The multicenter, randomized, placebo-controlled trial will enroll 129 patients across Europe, the United States, and Canada to assess both symptom relief and structural benefits. - The study represents the first human evaluation of a potential disease-modifying osteoarthritis drug targeting GLP-1 pathways, with topline results expected in the second half of 2026. - Primary endpoints focus on knee pain reduction at weeks 4 and 12, while secondary objectives include synovial health assessment via contrast-enhanced MRI.
- Health Canada has approved 4Moving Biotech's INFLAM MOTION Phase 2a clinical trial for 4P004, a GLP-1 analog designed for intra-articular use in knee osteoarthritis patients. - The multicenter, randomized, double-blind study will enroll 129 patients across the EU, US, and Canada to evaluate 4P004's potential as the first disease-modifying osteoarthritis drug (DMOAD). - 4P004 targets multiple joint tissues with analgesic, anti-inflammatory, anti-catabolic, and anabolic properties, potentially slowing disease progression and improving joint function.
